DCP
VRDN icon

Davern Capital Partners’s Viridian Therapeutics VRDN Stock Holding History

Davern Capital Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-302,457
Closed -$5.92M – 20
2026
Q1 		$5.92M Buy
302,457
+40,842
+16% +$1.21M 1.62% 17
2025
Q4 		$8.14M Buy
+261,615
New +$7.18M 2.63% 11

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Davern Capital Partners's VRDN Position: Q2 2026 in Review

Davern Capital Partners sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 302,457 shares — an estimated $5.92M sold.

Davern Capital Partners first reported a position in VRDN in Q4 2025 and held it in 2 quarters. The position peaked at $8.14M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Davern Capital Partners reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Davern Capital Partners sold 302,457 Viridian Therapeutics shares in Q2 2026, an estimated $5.92M.
  • Davern Capital Partners first reported a position in Viridian Therapeutics in Q4 2025 and held it in 2 quarters.
  • Davern Capital Partners's Viridian Therapeutics position peaked at $8.14M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Davern Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.